Botulinum toxin type A products are not interchangeable: a review of the evidence

References

• ScottABBotulinum toxin injection into extraocular muscles as an alternative to strabismus surgeryOphthalmology19808710104410497243198
   PubMed Web of Science ®Google Scholar
• SchellekensHFollow-on biologics: challenges of the “next generation”Nephrol Dial Transplant200520Suppl 4iv31iv3615827057
   PubMed Web of Science ®Google Scholar
• WoodcockJGriffinJBehrmanRThe FDA’s assessment of follow-on protein products: a historical perspectiveNat Rev Drug Discov20076643744217633790
   PubMed Web of Science ®Google Scholar
• LedfordHBiotechs go generic: the same but differentNature2007449716027427617882194
   PubMed Web of Science ®Google Scholar
• Genzyme CorporationGenzyme provides details of October Myozyme (alglucosidase alfa) Advisory Panel meeting and additional regulatory updates [press release]Cambridge, MAGenzyme Corporation9232008 Available from: http://news.genzyme.com/press-release/genzyme-provides-details-october-myozyme-alglucosidase-alfa-advisory-panel-meeting-andAccessed September 17, 2013
   Google Scholar
• SchellekensHWhen biotech proteins go off-patentTrends Biotechnol200422840641015283985
   PubMed Web of Science ®Google Scholar
• SchantzEJJohnsonEAProperties and use of botulinum toxin and other microbial neurotoxins in medicineMicrobiol Rev199256180991579114
   PubMedGoogle Scholar
• SchantzEJJohnsonEABotulinum toxin: the story of its development for the treatment of human diseasePerspect Biol Med19974033173279167258
   PubMed Web of Science ®Google Scholar
• BOTOX^® (onabotulinumtoxinA) [prescribing information]Irvine, CAAllergan, Inc2013
   Google Scholar
• ZhangLLinWJLiSAokiKRComplete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strainGene2003315213214557061
   PubMed Web of Science ®Google Scholar
• Fernández-SalasEWangJMolinaYNelsonJBJackyBPAokiKRBotulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassayPLoS One2012711e4951623185348
   PubMed Web of Science ®Google Scholar
• LietzowMAGielowETLeDZhangJVerhagenMFSubunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresisProtein J2008277–842042519020965
   PubMed Web of Science ®Google Scholar
• HambletonPClostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical useJ Neurol1992239116201311751
   PubMed Web of Science ®Google Scholar
• PanjwaniNO’KeeffeRPickettABiochemical, functional and potency characteristics of type A botulinum toxin in clinical useBotulinum J200811153166
   Google Scholar
• Ipsen, LtdDysport Summary of Product Characteristics [webpage on the Internet]Surrey, UKDatapharm Communications Ltd2013 Available from: http://www.medicines.org.uk/emc/medicine/870Accessed July 13, 2013
   Google Scholar
• Dysport^® (abobotulinumtoxinA) [prescribing information]Boulogne-BillancourtIpsen Biopharm Ltd2012
   Google Scholar
• Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research (CDER) Application #125274 Chemistry reviews BLA STN 125286/0 Reloxin (Botulinum Toxin Type A)Silver Spring, MDCenter for Drug Evaluation and Research2009 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/125274s000_ChemR.pdfAccessed October 21, 2013
   Google Scholar
• RoggenkämperPJostWHBihariKComesGGrafeSNT 201 Blepharospasm Study TeamEfficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasmJ Neural Transm2006113330331215959841
   PubMed Web of Science ®Google Scholar
• Xeomin (incobotulinumtoxinA) [prescribing information]Frankfurt am MainMerz Pharmaceuticals, LLC2013
   Google Scholar
• FrevertJDresslerDComplexing proteins in botulinum toxin type A drugs: a help or a hindrance?Biologics2010432533221209727
   PubMedGoogle Scholar
• DresslerDManderGFinkKMeasuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assayJ Neural Transm20121191131521971766
   PubMed Web of Science ®Google Scholar
• SakaguchiGKozakiSOhishiIStructure and function of botulinum toxinsAIoufJEBacterial Protein ToxinsLondonAcademic Press1984435443
   Google Scholar
• HathewayCBacterial sources of clostridial neurotoxinsSimpsonLLBotulinum Neurotoxin and Tetanus ToxinSan Diego, CAAcademic Press1989424
   Google Scholar
• Das GuptaBRSugiyamaHRole of a protease in natural activation of Clostridium botulinum neurotoxinInfect Immun1972645875904564288
   PubMed Web of Science ®Google Scholar
• WHO international biological reference preparations [webpage on the Internet]GenevaWorld Health Organization Available from: http://www.who.int/biologicals/reference_preparations/en/Accessed October 24, 2013
   Google Scholar
• InoueKFujinagaYWatanabeTMolecular composition of Clostridium botulinum type A progenitor toxinsInfect Immun1996645158915948613365
   PubMed Web of Science ®Google Scholar
• OhishiISugiiSSakaguchiGOral toxicities of Clostridium botulinum toxins in response to molecular sizeInfect Immun1977161107109326664
   PubMed Web of Science ®Google Scholar
• WagmanJBatemanJBBotulinum type A toxin: properties of a toxic dissociation productArch Biochem Biophys195345237538313081146
   PubMed Web of Science ®Google Scholar
• CaiSSarkarHKSinghBREnhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitolBiochemistry199938216903691010346912
   PubMed Web of Science ®Google Scholar
• EiseleKHFinkKVeyMTaylorHVStudies on the dissociation of botulinum neurotoxin type A complexesToxicon201157455556521195107
   PubMed Web of Science ®Google Scholar
• ScopesRKProtein Purification: Principles and Practice3rd edNew YorkSpringer1994
   Google Scholar
• ChenFKuziemkoGMAmersdorferPWongCMarksJDStevensRCAntibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed formsInfect Immun1997655162616309125539
   PubMed Web of Science ®Google Scholar
• GöschelHWohlfarthKFrevertJDenglerRBigalkeHBotulinum A toxin therapy: neutralizing and nonneutralizing antibodies – therapeutic consequencesExp Neurol19971471961029294406
   PubMed Web of Science ®Google Scholar
• KukrejaRChangTWCaiSImmunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteinsToxicon200953661662419673075
   PubMed Web of Science ®Google Scholar
• JoshiSGEliasMSinghAModulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragmentsNeuroscience201117920822221277940
   PubMed Web of Science ®Google Scholar
• ZbindenGFlury-RoversiMSignificance of the LD50-test for the toxicological evaluation of chemical substancesArch Toxicol198147277997271444
   PubMed Web of Science ®Google Scholar
• McLellanKDasREEkongTASesardicDTherapeutic botulinum type A toxin: factors affecting potencyToxicon19963499759858896190
   PubMed Web of Science ®Google Scholar
• HuntTClarkeKPotency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type AClin Neuropharmacol2009321283118978494
   PubMed Web of Science ®Google Scholar
• SesardicDLeungTGaines DasRRole for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxinBiologicals200331426527614624797
   PubMed Web of Science ®Google Scholar
• BrownMNicholsonGArdilaMCComparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulationsJ Neural Transm2013120229129822842675
   PubMed Web of Science ®Google Scholar
• HuntTClarkeKRuppDShimizuGWeidlerJ50-U incobotulinumtoxinA drug product demonstrates lower potency when compared to 50-U onabotulinumtoxinA drug product with concurrent lower light-chain activity and atypical substrate cleavagePoster presented at: 6th European Master’s in Aesthetic and Anti-Aging MedicineOctober 15–17, 2010Paris, France
   Google Scholar
• BOTOX® [prescribing information]Irvine, CAAllergan, Inc2001
   Google Scholar
• Allergan, LtdBOTOX^® 100 U. Summary of product characteristics [webpage on the Internet]Surrey, UKDatapharm Communications Ltd2013 [updated December 12, 2012]. Available from: http://www.medicines.org.uk/emc/medicine/112Accessed July 22, 2013
   Google Scholar
• BOTOX^® (onabotulinumtoxinA) [prescribing information]Buenos Aires, ArgentinaAllergan, Inc2011
   Google Scholar
• Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc) [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2013 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htmAccessed May 20, 2014
   Google Scholar
• AokiKRRanouxDWisselJUsing translational medicine to understand clinical differences between botulinum toxin formulationsEur J Neurol200613Suppl 4101917112345
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJSaidSDose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in femalesDermatol Surg2005314414422 discussion 42215871316
   PubMed Web of Science ®Google Scholar
• AscherBZakineBKestemontPBaspeyrasMBougaraASantiniJA multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar linesJ Am Acad Dermatol200451222323315280841
   PubMed Web of Science ®Google Scholar
• Fulford-SmithAGallagherCJBrinMFMulticentre, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown linesDerm Surg201339711181119
   Web of Science ®Google Scholar
• SampaioCCostaJFerreiraJJClinical comparability of marketed formulations of botulinum toxinMov Disord200419Suppl 8S129S13615027065
   PubMed Web of Science ®Google Scholar
• SampaioCFerreiraJJSimõesFDYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A – Dysport and Botox – assuming a ratio of 4:1Mov Disord1997126101310189399229
   PubMed Web of Science ®Google Scholar
• RanouxDGuryCFondaraiJMasJLZuberMRespective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystoniaJ Neurol Neurosurg Psychiatry200272445946211909903
   PubMed Web of Science ®Google Scholar
• MarchettiAMagarRFindleyLRetrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE studyMov Disord200520893794415810022
   PubMed Web of Science ®Google Scholar
• NüssgensZRoggenkämperPComparison of two botulinum-toxin preparations in the treatment of essential blepharospasmGraefes Arch Clin Exp Ophthalmol199723541971999143885
   PubMed Web of Science ®Google Scholar
• OdergrenTHjaltasonHKaakkolaSA double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystoniaJ Neurol Neurosurg Psychiatry19986416129436720
   PubMed Web of Science ®Google Scholar
• BeneckeRJostWHKanovskyPRuzickaEComesGGrafeSA new botulinum toxin type A free of complexing proteins for treatment of cervical dystoniaNeurology200564111949195115955951
   PubMed Web of Science ®Google Scholar
• SattlerGCallanderMJGrablowitzDNoninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown linesDermatol Surg201036Suppl 42146215421134045
   PubMed Web of Science ®Google Scholar
• Moers-CarpiMDirschkaTFeller-HepptGA randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar linesJ Cosmet Laser Ther201214629630323057624
   PubMed Web of Science ®Google Scholar
• SnapinnSMNoninferiority trialsCurr Control Trials Cardiovasc Med200011192111714400
   PubMedGoogle Scholar
• FrevertJContent of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs R D2010102677320698714
   PubMedGoogle Scholar
• LeeNJMcDonaghMChanBPetersonKThakurtaSDrug class review Topical calcineurin inhibitors Final ReportPortland, OROregon Health and Science University2008 Available from: http://www.ncbi.nlm.nih.gov/books/NBK10462/pdf/TOC.pdfAccessed June 5, 2014
   Google Scholar
• PragerWRapplTPhase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown linesJ Cosmet Dermatol201211426727123174049
   PubMed Web of Science ®Google Scholar
• WabbelsBJostWHRoggenkamperPDifficulties with differentiating botulinum toxin treatment effects in essential blepharospasmJ Neural Transm2011118692594321221669
   PubMed Web of Science ®Google Scholar
• HobartJCCanoSJZajicekJPThompsonAJRating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendationsLancet Neurol20076121094110518031706
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJLoweNJBOTOX® Glabellar Lines I and II, Groups SOne-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar linesJ Clin Res20047120
   Google Scholar
• JostWHBlümelJGrafeSBotulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystoniaDrugs200767566968317385940
   PubMed Web of Science ®Google Scholar
• LorencZPKenkelJMFagienSA review of AbobotulinumtoxinA (Dysport)Aesthet Surg J201333Suppl 113S17S23515194
   PubMed Web of Science ®Google Scholar
• BeerKRBoydCPatelRKBowenBJamesSPBrinMFRapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar linesJ Drugs Dermatol2011101394421197522
   PubMed Web of Science ®Google Scholar
• KarsaiSAdrianRHammesSThimmJRaulinCA randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activityArch Dermatol2007143111447144918025375
   PubMedGoogle Scholar
• BlitzerABrinMFUse of botulinum toxin for diagnosis and management of cricopharyngeal achalasiaOtolaryngol Head Neck Surg199711633283309121784
   PubMed Web of Science ®Google Scholar
• NestorMSAblonGRComparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement StandardJ Drugs Dermatol201110101148115721968665
   PubMed Web of Science ®Google Scholar
• RapplTParviziDFriedlHOnset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind studyClin Cosmet Investig Dermatol20136211219
   Google Scholar
• JankovicJSchwartzKBotulinum toxin injections for cervical dystoniaNeurology19904022772802300249
   PubMed Web of Science ®Google Scholar
• BrashearALewMFDykstraDDSafety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystoniaNeurology19995371439144610534248
   PubMed Web of Science ®Google Scholar
• BrashearAWattsMWMarchettiAMagarRLauHWangLDuration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart reviewClin Ther200022121516152411192142
   PubMed Web of Science ®Google Scholar
• LowePPatnaikRLoweNComparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized studyJ Am Acad Dermatol200655697598017097394
   PubMed Web of Science ®Google Scholar
• GlogauRKaneMBeddingfieldFOnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar linesDermatol Surg201238111794180323106853
   PubMed Web of Science ®Google Scholar
• BanegasRAFaracheFRancatiAThe South American Glabellar Experience Study (SAGE): A Multicenter Retrospective Analysis of Real-World Treatment Patterns Following the Introduction of IncobotulinumtoxinA in ArgentinaAesthet Surg J20133371039104523990584
   PubMed Web of Science ®Google Scholar
• ChunduryRVCouchSMHoldsJBComparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasmOphthal Plast Reconstr Surg2013293205207
   PubMed Web of Science ®Google Scholar
• CliffSHJudodihardjoHEltringhamEDifferent formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized studyJ Cosmet Dermatol200871505418254812
   PubMedGoogle Scholar
• PickettADoddSRzanyBConfusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applicationsJ Cosmet Laser Ther200810318118318608706
   PubMed Web of Science ®Google Scholar
• WalkerFOBotulinum toxin therapy for cervical dystoniaPhys Med Rehabil Clin N Am2003144749766vi14580035
   PubMedGoogle Scholar
• HouJJankovicJBotulinum toxin treatment in tremorsBrinMFHallettMJankovicJScientific and Therapeutic Aspects of Botulinum ToxinPhiladelphiaLippincott Williams & Wilkins2002323335
   Google Scholar
• Ramirez-CastanedaJJankovicJComellaCDashtipourKFernandezHHMariZDiffusion, spread, and migration of botulinum toxinMov Disord201328131775178323868503
   PubMed Web of Science ®Google Scholar
• CotéTRMohanAKPolderJAWaltonMKBraunMMBotulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic casesJ Am Acad Dermatol200553340741516112345
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationL etter Re: Docket No FDA-2008-P-0061. April 30, 2009Silver Spring, MDUS Food and Drug Administration2009 Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM143989.pdfAccessed October 23, 2013
   Google Scholar
• KarsentyGBaverstockRCarlsonKTechnical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedureInt J Clin Pract201468673174224472109
   PubMedGoogle Scholar
• PloumisAVarvarousisDKonitsiotisSBerisAEffectiveness of botulinum toxin injection with and without needle electromyographic guidance for the treatment of spasticity in hemiplegic patients: a randomized controlled trialDisabil Rehabil201436431331823672209
   PubMed Web of Science ®Google Scholar
• CarruthersACarruthersJCohenJDilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?Dermatol Surg2007331 SpecS97S10417241422
   PubMed Web of Science ®Google Scholar
• AokiKRA comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in miceToxicon200139121815182011600142
   PubMed Web of Science ®Google Scholar
• DoddSLRowellBAVrabasISArrowsmithRJWeatherillPJA comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle functionEur J Neurol19985218118610210830
   PubMed Web of Science ®Google Scholar
• RosalesRLBigalkeHDresslerDPharmacology of botulinum toxin: differences between type A preparationsEur J Neurol200613Suppl 121016417591
   PubMed Web of Science ®Google Scholar
• ChungMESongDHParkJHComparative study of biological activity of four botulinum toxin type A preparations in miceDermatol Surg2013391 Pt 215516423301819
   PubMed Web of Science ®Google Scholar
• Trindade de AlmeidaARMarquesEde AlmeidaJCunhaTBorasoRPilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosisDermatol Surg2007331 SpecS37S4317241413
   PubMed Web of Science ®Google Scholar
• HexselDDal’FornoTHexselCDo PradoDZLimaMMA randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type ADermatol Surg2008341525918053050
   PubMed Web of Science ®Google Scholar
• NaumannMLoweNJBotulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trialBMJ2001323731359659911557704
   PubMed Web of Science ®Google Scholar
• HexselDHexselCSiegaCSchilling-SouzaJRottaFTRodriguesTCFields of effects of 2 commercial preparations of botulinum toxin type A at equal labeled unit doses: a double-blind randomized trialJAMA Dermatol2013149121386139124108521
   PubMed Web of Science ®Google Scholar
• KranzGHaubenbergerDVollerBRespective potencies of Botox and Dysport in a human skin model: a randomized, double-blind studyMov Disord200924223123618951439
   PubMed Web of Science ®Google Scholar
• RystedtASwartlingCFarnstrandCNaverHEquipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosisActa Derm Venereol200888545846118779882
   PubMed Web of Science ®Google Scholar
• RystedtAKarlqvistMBertilssonMNaverHSwartlingCEffect of botulinum toxin concentration on reduction in sweating: a randomized, double-blind studyActa Derm Venereol201393667467823694974
   PubMed Web of Science ®Google Scholar
• KerscherMRollSBeckerAWigger-AlbertiWComparison of the spread of three botulinum toxin type A preparationsArch Dermatol Res2012304215516122002325
   PubMed Web of Science ®Google Scholar
• BentivoglioARIalongoTBoveFDe NigrisFFasanoARetrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending storyNeurol Sci201233226126721710123
   PubMed Web of Science ®Google Scholar
• JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology20036071186118812682332
   PubMed Web of Science ®Google Scholar
• BrinMFComellaCLJankovicJLaiFNaumannMCD-017 BoNTA Study GroupLong-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMov Disord200823101353136018546321
   PubMed Web of Science ®Google Scholar
• NaumannMBooLMAckermanAHGallagherCJImmunogenicity of botulinum toxinsJ Neural Transm2013120227529023008029
   PubMed Web of Science ®Google Scholar
• FDA Approval Package for Xeomin^® (2010) (incobotulinumtoxinA) Injection vol Application Number 125360 [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2010 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125360s0000TOC.cfmAccessed June 5, 2014
   Google Scholar
• GelbDJYoshimuraDMOlneyRKLowensteinDHAminoffMJChange in pattern of muscle activity following botulinum toxin injections for torticollisAnn Neurol19912943703761929208
   PubMed Web of Science ®Google Scholar
• BrashearABerganKWojcieszekJSiemersERAmbrosiusWPatients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type AMov Disord200015115015310634256
   PubMed Web of Science ®Google Scholar
• NaumannMCarruthersACarruthersJMeta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indicationsMov Disord201025132211221820737546
   PubMed Web of Science ®Google Scholar
• MohindruABullochSKronfeldNJamesCAnalysis of clinical and non-clinical, peer-reviewed published studies investigating the use of commercially available botulinum toxins: an online and offline literature reviewPoster presented at: 2nd International Congress on Treatment of DystonialMay 9–12 May; 2013Hannover, Germany
   Google Scholar
• NaumannMLoweNJKumarCRHammHHyperhidrosis Clinical Investigators GroupBotulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective studyArch Dermatol2003139673173612810503
   PubMedGoogle Scholar
• GinsbergDGousseAKeppenneVPhase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivityJ Urol201218762131213922503020
   PubMed Web of Science ®Google Scholar
• CoelhoACruzFCruzCDAvelinoASpread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin actionEur Urol20126161178118422306320
   PubMed Web of Science ®Google Scholar
• CoelhoACruzFCruzCDAvelinoAEffect of onabotulinumtoxinA on intramural parasympathetic ganglia: an experimental study in the guinea pig bladderJ Urol201218731121112622266001
   PubMed Web of Science ®Google Scholar
• DurhamPLCadyRCadyRRegulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapyHeadache20044413542 discussion 42–3314979881
   PubMed Web of Science ®Google Scholar
• CollinsVMDalyDMLiaskosMOnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urotheliumBJU Int201311271018102623937318
   PubMed Web of Science ®Google Scholar
• AuroraSKDodickDWTurkelCCPREEMPT 1 Chronic Migraine Study GroupOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia201030779380320647170
   PubMed Web of Science ®Google Scholar
• DodickDWTurkelCCDeGryseREPREEMPT Chronic Migraine Study GroupOnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical programHeadache201050692193620487038
   PubMed Web of Science ®Google Scholar
• DmochowskiRChappleCNittiVWEfficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trialJ Urol201018462416242220952013
   PubMed Web of Science ®Google Scholar
• Information for Healthcare Professionals: OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc) [webpage on the Internet]US Food and Drug Administration2009 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htmAccessed October 10, 2013
   Google Scholar
• PickettAMewiesMSerious issues relating to the clinical use of unlicensed botulinum toxin productsJ Am Acad Dermatol200961114915019539854
   PubMed Web of Science ®Google Scholar
• HuntTClarkeKPotency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency testJ Am Acad Dermatol200858351751818280358
   PubMed Web of Science ®Google Scholar
• ChertowDSTanETMaslankaSEBotulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparationJAMA2006296202476247917119144
   PubMed Web of Science ®Google Scholar